<unk>  is an isocitrate dehydrogenase-1 (IDH1) inhibitor that is FDA approved for the treatment of acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test in adult patients with newly-diagnosed AML who are ≥ 75 years old or who have comorbidities that preclude use of intensive induction chemotherapy and adult patients with relapsed or refractory AML. There is a Black Box Warning for this drug as shown here.  Common adverse reactions include fatigue, arthralgia, leukocytosis, diarrhea, edema, nausea, dyspnea, mucositis, electrocardiogram QT prolonged, rash, cough, decreased appetite, myalgia, constipation, and pyrexia.
Ivosidenib
Enasidenib
Brigatinib
Fostamatinib
Lorlatinib
Dabrafenib mesylate
Lenvatinib
Encorafenib